Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

医学 帕妥珠单抗 内科学 曲妥珠单抗 临床终点 不利影响 肿瘤科 实体瘤疗效评价标准 贫血 队列 危险系数 癌症 进行性疾病 临床试验 置信区间 乳腺癌 疾病
作者
Timothy Lewis Cannon,Michael Rothe,Pam K. Mangat,Elizabeth Garrett‐Mayer,Vi K. Chiu,Jimmy J. Hwang,Namrata Vijayvergia,Olatunji B. Alese,Elie G. Dib,Herbert L. Duvivier,Kelsey Klute,Vaibhav Sahai,Eugene Ahn,Pablo M. Bedano,Deepti Behl,Sarah Sinclair,Ramya Thota,Walter J. Urba,Eddy S. Yang,Gina N. Grantham
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (27): 3228-3237 被引量:6
标识
DOI:10.1200/jco.23.02078
摘要

PURPOSE Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with biliary tract cancer (BTC) with ERBB2/3 amplification, overexpression, or mutation treated with pertuzumab plus trastuzumab are reported. METHODS Eligible patients had advanced BTC, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with ERBB2/3 alterations, and a lack of standard treatment options. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease of at least 16+ weeks duration (SD16+) according to RECIST v1.1. Secondary end points included OR, progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS Twenty-nine patients were enrolled from February 2017 to January 2022, and all had advanced BTC with an ERBB2/3 alteration. One patient was not evaluable for efficacy. One complete response, eight partial responses, and two SD16+ were observed for DC and OR rates of 40% (90% CI, 27 to 100) and 32% (95% CI, 16 to 52), respectively. The null hypothesis of 15% DC rate was rejected ( P = .0015). Four patients had at least one grade 3 adverse event (AE) or serious AE at least possibly related to treatment: anemia, diarrhea, infusion-related reaction, and fatigue. CONCLUSION Pertuzumab plus trastuzumab met prespecified criteria to declare a signal of activity in patients with BTC and ERBB2/3 amplification, overexpression, or mutation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
songvv发布了新的文献求助10
刚刚
一一一应助Bin_Liu采纳,获得10
1秒前
麻果完成签到,获得积分10
3秒前
OER完成签到,获得积分10
3秒前
伦语完成签到,获得积分20
3秒前
中陆完成签到,获得积分10
4秒前
5秒前
莫西莫西完成签到,获得积分10
7秒前
9秒前
量子星尘发布了新的文献求助10
10秒前
xjh完成签到,获得积分10
10秒前
10秒前
lbnzd8g完成签到,获得积分10
12秒前
中海完成签到,获得积分10
12秒前
Ww完成签到,获得积分10
12秒前
伶俐不二完成签到,获得积分10
12秒前
XIAOJU_U完成签到 ,获得积分10
13秒前
马士全发布了新的文献求助10
14秒前
MQ完成签到,获得积分10
14秒前
单纯血茗发布了新的文献求助10
16秒前
善学以致用应助田南松采纳,获得10
16秒前
不如看海完成签到 ,获得积分10
17秒前
可靠的南露完成签到,获得积分10
18秒前
gg完成签到,获得积分10
18秒前
AU完成签到,获得积分10
20秒前
与淇完成签到,获得积分10
20秒前
开心祯祯完成签到,获得积分10
20秒前
马士全完成签到,获得积分10
21秒前
Qian完成签到 ,获得积分10
21秒前
degre完成签到 ,获得积分10
21秒前
W~舞完成签到,获得积分10
22秒前
我的文献呢应助pz采纳,获得30
23秒前
潇洒的如松完成签到,获得积分10
24秒前
逆流的鱼完成签到 ,获得积分10
25秒前
英俊的铭应助jiaolulu采纳,获得10
28秒前
29秒前
榛糕李完成签到,获得积分10
31秒前
liuj完成签到,获得积分10
31秒前
anhuiwsy完成签到 ,获得积分10
33秒前
爱咋咋地完成签到 ,获得积分10
33秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022